MedEdTalks - Pulmonology

In this podcast, expert clinicians will discuss best practice for improving patient-provider communication to improve adherence to IPF therapies.

In this podcast, expert clinicians will discuss the most recent data regarding long-term outcomes with current therapies for IPF.

In this podcast, expert clinicians will discuss evidence-based best practices for making early and accurate diagnoses in IPF.

In this podcast, expert clinicians will discuss the strategies to improve patients adherence to therapy in SSc-ILD.

In this podcast, expert clinicians will discuss evidence-based recommendations for the treatment of SSc-ILD.

In this podcast, expert clinicians will discuss best practices in the diagnosis of SSc-ILD.

In this podcast, expert clinicians will discuss the prevalence and burden of SSc-ILD.

In this podcast, expert clinicians will discuss treatment for a patient with refractory Mycobacterium avium complex lung disease despite many months of guidelines-based therapy. 

For CME Credit, complete activity here: https://tinyurl.com/LungMET2

In this podcast, expert clinicians will discuss treatment for Mycobacterium avium complex lung infection in a patient with underlying granulomatosis with polyangiitis affecting the lungs. 

For CME Credit, complete activity here:

https://tinyurl.com/LungMET1

Interstitial lung disease (ILD) describes a group of over more than 200 rare pulmonary conditions characterized by fibrosis of the lung. ILD can have several causes, including environmental antigens, bacterial, viral, and fungal infections, gastroesophageal reflux, occupational hazards (eg, asbestos), or a connective tissue disease (CTD). Patients with systemic sclerosis (SSc), rheumatoid arthritis (RA), or poly-/dermatomyositis (PM/DM), have the greatest risk of developing CTD-associated ILD. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, though patients who develop a progressive-fibrosing phenotype ILD (PF-ILD) are subject to similar outcomes. With historically limited treatment options, pulmonologists, rheumatologists, radiologists, and other providers who care for patients with PF-ILD are unaware of how new options and data for patients with IPF may benefit patients with PF-ILD. In this educational activity, expert clinicians will discuss a challenging case on treating a patient with PF-ILD.

Transcript: https://tinyurl.com/PF-ILD4Transcript

For CME Credit, complete activity here: https://tinyurl.com/PF-ILD4

Interstitial lung disease (ILD) describes a group of over more than 200 rare pulmonary conditions characterized by fibrosis of the lung. ILD can have several causes, including environmental antigens, bacterial, viral, and fungal infections, gastroesophageal reflux, occupational hazards (eg, asbestos), or a connective tissue disease (CTD). Patients with systemic sclerosis (SSc), rheumatoid arthritis (RA), or poly-/dermatomyositis (PM/DM), have the greatest risk of developing CTD-associated ILD. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, though patients who develop a progressive-fibrosing phenotype ILD (PF-ILD) are subject to similar outcomes. With historically limited treatment options, pulmonologists, rheumatologists, radiologists, and other providers who care for patients with PF-ILD are unaware of how new options and data for patients with IPF may benefit patients with PF-ILD. In this educational activity, expert clinicians will discuss a challenging case on diagnosing a patient with PF-ILD.

Transcript: https://tinyurl.com/PF-ILD3Transcript

For CME Credit, complete activity here: https://tinyurl.com/PF-ILD3

Interstitial lung disease (ILD) describes a group of over more than 200 rare pulmonary conditions characterized by fibrosis of the lung. ILD can have several causes, including environmental antigens, bacterial, viral, and fungal infections, gastroesophageal reflux, occupational hazards (eg, asbestos), or a connective tissue disease (CTD). Patients with systemic sclerosis (SSc), rheumatoid arthritis (RA), or poly-/dermatomyositis (PM/DM), have the greatest risk of developing CTD-associated ILD. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, though patients who develop a progressive-fibrosing phenotype ILD (PF-ILD) are subject to similar outcomes. With historically limited treatment options, pulmonologists, rheumatologists, radiologists, and other providers who care for patients with PF-ILD are unaware of how new options and data for patients with IPF may benefit patients with PF-ILD. In this educational activity, expert clinicians will discuss a challenging case on treating a patient with PF-ILD.

Transcript: https://tinyurl.com/PF-ILD2Transcript

For CME Credit, complete activity here: https://tinyurl.com/PF-ILD2

Interstitial lung disease (ILD) describes a group of over more than 200 rare pulmonary conditions characterized by fibrosis of the lung. ILD can have several causes, including environmental antigens, bacterial, viral, and fungal infections, gastroesophageal reflux, occupational hazards (eg, asbestos), or a connective tissue disease (CTD). Patients with systemic sclerosis (SSc), rheumatoid arthritis (RA), or poly-/dermatomyositis (PM/DM), have the greatest risk of developing CTD-associated ILD. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, though patients who develop a progressive-fibrosing phenotype ILD (PF-ILD) are subject to similar outcomes. With historically limited treatment options, pulmonologists, rheumatologists, radiologists, and other providers who care for patients with PF-ILD are unaware of how new options and data for patients with IPF may benefit patients with PF-ILD. In this educational activity, expert clinicians will discuss a challenging case on diagnosing a patient with PF-ILD.

Transcript: https://tinyurl.com/PF-ILD1Transcript

For CME Credit, complete activity here: https://tinyurl.com/PF-ILD1

The intended audience for this series is pulmonologists, internists, rheumatologists and other health care professionals involved in the management of patients with progressive fibrosing interstitial lung disease (PF-ILD).